Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 6, Issue 16
August 23 2022
Issue Cover

Table of Contents

DRUG ADVANCES

The odyssey of pacritinib in myelofibrosis
Sangeetha Venugopal,John Mascarenhas
View Articletitled, The odyssey of pacritinib in myelofibrosis

SYSTEMATIC REVIEW

ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis
Michela Giustozzi,Giulia Proietti,Cecilia Becattini,Fausto Roila,Giancarlo Agnelli,Mario Mandalà
View Articletitled, ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis
Supplemental data

CLINICAL TRIALS AND OBSERVATIONS

Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: an LOC network study
Clinical Trials & Observations
Paul Lesueur,Gandhi Damaj,Khê Hoang-Xuan,Virginie Roland,Anna Schmitt,Olivier Chinot,Michel Fabbro,Philippe Agapé,Cécile Moluçon-Chabrot,Safia Chebrek,Agusti Alentorn,Loic Feuvret,Daniel Delgadillo,Dinu Stefan,Sylvain Choquet,Lucia Nichelli,Karima Mokhtari,Bertrand Mathon,Sylvain Dureau,Carole Soussain,Caroline Houillier
View Articletitled, Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: an LOC network study
Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease
Frits van Rhee,Adam Rosenthal,Karan Kanhai,Rabecka Martin,Katherine Nishimura,Antje Hoering,David C. Fajgenbaum
View Articletitled, Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease
Supplemental data
Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis
Fotini Vogiatzi,Julia Heymann,Kristina Müller,Dorothee Winterberg,Aneta Drakul,Thies Rösner,Lennart Lenk,Michelle Heib,Carina Lynn Gehlert,Gunnar Cario,Martin Schrappe,Alexander Claviez,Beat Bornhauser,Jean-Pierre Bourquin,Simon Bomken,Dieter Adam,Fabian-Simon Frielitz,Britta Maecker-Kolhoff,Martin Stanulla,Thomas Valerius,Matthias Peipp,Christian Kellner,Denis M. Schewe
View Articletitled, Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis
Supplemental data
Dominant epitopes presented by prevalent HLA alleles permit wide use of banked CMVpp65 T cells in adoptive therapy
Aisha N. Hasan,Ekaterina Doubrovina,Rosa Sottile,Susan Prockop,Martin G. Klatt,Glenn Heller,Annamalai Selvakumar,Lorna Barnett,Katharine C. Hsu,Richard J. O’Reilly
View Articletitled, Dominant epitopes presented by prevalent HLA alleles permit wide use of banked CMVpp65 T cells in adoptive therapy
Supplemental data

LYMPHOID NEOPLASIA

A unifying hypothesis for PNMZL and PTFL: morphological variants with a common molecular profile
Julia Salmeron-Villalobos,Caoimhe Egan,Vanessa Borgmann,Inga Müller,Blanca Gonzalez-Farre,Joan Enric Ramis-Zaldivar,Dominik Nann,Olga Balagué,Mónica López-Guerra,Dolors Colomer,Ilske Oschlies,Wolfram Klapper,Selina Glaser,Young Hyeh Ko,Irina Bonzheim,Reiner Siebert,Falko Fend,Stefania Pittaluga,Elias Campo,Itziar Salaverria,Elaine S. Jaffe,Leticia Quintanilla-Martinez
View Articletitled, A unifying hypothesis for PNMZL and PTFL: morphological variants with a common molecular profile
Supplemental data
Single-cell spatial analysis of tumor immune architecture in diffuse large B-cell lymphoma
Anthony R. Colombo,Monirath Hav,Mohan Singh,Alexander Xu,Alicia Gamboa,Tucker Lemos,Erik Gerdtsson,Denaly Chen,Jane Houldsworth,Rita Shaknovich,Tomohiro Aoki,Lauren Chong,Katsuyoshi Takata,Elizabeth A. Chavez,Christian Steidl,James Hicks,Peter Kuhn,Imran Siddiqi,Akil Merchant
View Articletitled, Single-cell spatial analysis of tumor immune architecture in diffuse large B-cell lymphoma
Supplemental data
Nurselike cells sequester B cells in disorganized lymph nodes in chronic lymphocytic leukemia via alternative production of CCL21
Rim Zaaboub,Lene Vimeux,Vincent Contremoulins,Florence Cymbalista,Vincent Lévy,Emmanuel Donnadieu,Nadine Varin-Blank,Antoine Martin,Elisabetta Dondi
View Articletitled, Nurselike cells sequester B cells in disorganized lymph nodes in chronic lymphocytic leukemia via alternative production of CCL21
Supplemental data
Comparative efficacy and tolerability of novel agents vs chemotherapy in relapsed and refractory T-cell lymphomas: a meta-analysis
Nazila Shafagati,Min J. Koh,Leora Boussi,Hyun J. Park,Robert Stuver,Paul Bain,Francine M. Foss,Changyu Shen,Salvia Jain
View Articletitled, Comparative efficacy and tolerability of novel agents vs chemotherapy in relapsed and refractory T-cell lymphomas: a meta-analysis
Supplemental data
Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma
Jessica S. Little,Muneerah M. Aleissa,Katherine Beluch,Isabel H. Gonzalez-Bocco,Francisco M. Marty,Jennifer Manne-Goehler,Sophia Koo,Sarah P. Hammond,Caron A. Jacobson
View Articletitled, Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma

MYELOID NEOPLASIA

HMGA2 expression defines a subset of human AML with immature transcriptional signature and vulnerability to G2/M inhibition
Céline Moison,Jean-François Spinella,Jalila Chagraoui,Vincent-Philippe Lavallée,Bernhard Lehnertz,Clarisse Thiollier,Isabel Boivin,Nadine Mayotte,Tara MacRae,Anne Marinier,Josée Hébert,Guy Sauvageau
View Articletitled, HMGA2 expression defines a subset of human AML with immature transcriptional signature and vulnerability to G2/M inhibition
Supplemental data

PLATELETS AND THROMBOPOIESIS

Cytokine pathway variants modulate platelet production: IFNA16 is a thrombocytosis susceptibility locus in humans
Dmitri V. Gnatenko,Zhaoyan Liu,Patrick Hearing,Sook-Young Sohn,Yetao Hu,Anna Falanga,Song Wu,Lisa E. Malone,Wei Zhu,Wadie F. Bahou
View Articletitled, Cytokine pathway variants modulate platelet production: <em>IFNA16</em> is a thrombocytosis susceptibility locus in humans
Supplemental data

THROMBOSIS AND HEMOSTASIS

Traumatic vessel injuries initiating hemostasis generate high shear conditions
Alexandra A. Yakusheva,Kirill R. Butov,Georgii A. Bykov,Gábor Závodszky,Anita Eckly,Fazly I. Ataullakhanov,Christian Gachet,Mikhail A. Panteleev,Pierre H. Mangin
View Articletitled, Traumatic vessel injuries initiating hemostasis generate high shear conditions
Supplemental data

TRANSPLANTATION

Prospective external validation of biomarkers to predict acute graft-versus-host disease severity
Clinical Trials & Observations
Marie Robin,Raphael Porcher,David Michonneau,Laetitia Taurines,Flore Sicre de Fontbrune,Aliénor Xhaard,Bastien Oriano,Aurélien Sutra Del Galy,Régis Peffault de Latour,Gérard Socié,Marie-Hélène Schlageter
View Articletitled, Prospective external validation of biomarkers to predict acute graft-versus-host disease severity
Supplemental data
ICOS immunoPET enables visualization of activated T cells and early diagnosis of murine acute gastrointestinal GvHD
Zunyu Xiao,Israt S. Alam,Federico Simonetta,Weiyu Chen,Lukas Scheller,Surya Murty,Juliane K. Lohmeyer,Teresa L. Ramos,Michelle L. James,Robert S. Negrin,Sanjiv S. Gambhir
View Articletitled, ICOS immunoPET enables visualization of activated T cells and early diagnosis of murine acute gastrointestinal GvHD
Supplemental data

RESEARCH LETTERS

The extent of residual WT HSPCs is associated with the degree of anemia in patients with SF3B1-mutated MDS-RS
Isabel Juliana F. Hofman,Teresa Mortera-Blanco,Pedro Luis Moura,Johanna Vestlund,Sigita Venckute Larsson,Edda M. Elvarsdottir,Gunilla Walldin,Magnus Tobiasson,Birgitta Sander,Marios Dimitriou,Sten-Eirik W. Jacobsen,Petter S. Woll,Martin Jädersten,Eva Hellström-Lindberg
View Articletitled, The extent of residual WT HSPCs is associated with the degree of anemia in patients with <em>SF3B1</em>-mutated MDS-RS
Supplemental data
CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy
Khushnuma Mullanfiroze,Arina Lazareva,Jan Chu,Lindsey Williams,Saskia Burridge,Juliana Silva,Robert Chiesa,Kanchan Rao,Giovanna Lucchini,Sara Ghorashian,Maeve O’Reilly,Ben Carpenter,Victoria Grandage,Rachael Hough,Claire Roddie,Persis J. Amrolia
View Articletitled, CD34<sup><strong>+</strong></sup>-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy
Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy
Kai Rejeski,Andreas Burchert,Gloria Iacoboni,Pierre Sesques,Lars Fransecky,Veit Bücklein,Corinna Trenker,Rafael Hernani,Ralph Naumann,Jonas Schäfer,Viktoria Blumenberg,Christian Schmidt,Kristina Sohlbach,Michael von Bergwelt-Baildon,Emmanuel Bachy,Pere Barba,Marion Subklewe
View Articletitled, Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy
Supplemental data
Rural-urban disparities in place of death in hematologic malignancies in the United States, 2003 to 2019
S. M. Qasim Hussaini,Amanda L. Blackford,Arjun Gupta,Ramy Sedhom,Sarah H. Cross,Haider J. Warraich,Thomas W. LeBlanc
View Articletitled, Rural-urban disparities in place of death in hematologic malignancies in the United States, 2003 to 2019
Supplemental data
Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study
Clinical Trials & Observations
Juan P. Alderuccio,Weiyun Z. Ai,John Radford,Melhem Solh,Kirit M. Ardeshna,Matthew A. Lunning,Brian T. Hess,Pier L. Zinzani,Anastasios Stathis,Carmelo Carlo-Stella,Mehdi Hamadani,Brad S. Kahl,David Ungar,Turk Kilavuz,Eric Yu,Yajuan Qin,Paolo F. Caimi
View Articletitled, Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study
Sexual violence as a precipitator of chronic pain in young adults with sickle cell disease
Maya Chopra,Jeannie Byrd,Kristin Wuichet,Michael R. DeBaun
View Articletitled, Sexual violence as a precipitator of chronic pain in young adults with sickle cell disease
Cellular distribution of mutations and association with disease risk in Langerhans cell histiocytosis without BRAFV600E
Clinical Trials & Observations
Paul Milne,Harshal Abhyankar,Brooks Scull,Preeti Singh,Rikhia Chakraborty,Carl E. Allen,Matthew Collin
View Articletitled, Cellular distribution of mutations and association with disease risk in Langerhans cell histiocytosis without <em>BRAF</em><sup>V600E</sup>
Supplemental data

COMMENTARIES

Emerging clinical trial designs may accelerate translation in hematology: lessons from COVID-19
Clinical Trials & Observations
Matthew D. Neal,Patrick R. Lawler,Ryan Zarychanski
View Articletitled, Emerging clinical trial designs may accelerate translation in hematology: lessons from COVID-19
Revision of RUNX1 variant curation rules
Simone Feurstein,Xi Luo,Mancy Shah,Taylor Walker,Nikita Mehta,David Wu,Lucy A. Godley,on behalf of the Myeloid Malignancy Variant Curation Expert Panel
View Articletitled, Revision of <em>RUNX1</em> variant curation rules
Supplemental data
Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma
Clinical Trials & Observations
Ulrich Jaeger,Constantine S. Tam,Peter Borchmann,Joseph P. McGuirk,Marianne Johansen,Edmund K. Waller,Samantha Jaglowski,Charalambos Andreadis,Stephen R. Foley,Jason R. Westin,Isabelle Fleury,P. Joy Ho,Stephan Mielke,Takanori Teshima,Gilles Salles,Stephen J. Schuster,Fiona He,Richard T. Maziarz,Sebastian Mayer,Shinichi Makita,Marie J. Kersten,Monalisa Ghosh,Nina Wagner-Johnston,Koji Kato,Paolo Corradini,Hideki Goto,Silvia Colicino,Abhijit Agarwal,Chiara Lobetti-Bodoni,Michael R. Bishop
View Articletitled, Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma
Supplemental data

ERRATUM

Vo P, Gooley, TA, Carpenter PA, et al. Prediction of outcomes after second-line treatment for acute graft-versus-host disease. Blood Adv. 2022;6(11):3220-3229.
View Articletitled, Vo P, Gooley, TA, Carpenter PA, et al. Prediction of outcomes after second-line treatment for acute graft-versus-host disease. <em>Blood Adv</em>. 2022;6(11):3220-3229.
  • Cover Image

    Cover Image

    issue cover

    The in situ spatial distribution of malignant cells within the tumor microenvironment in diffuse large B-cell lymphoma is classified by their distance to the immune interface using imaging mass cytometry. See the article by Colombo et al.

  • PDF Icon PDF LinkFront Matter
  • PDF Icon PDF LinkEditorial Board
All Issues

Advertisement intended for health care professionals

CAR T-cell expansion: harmful or helpful?
Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas
Utilizing Epigenetic Regulators to improve HSC-based lentiviral gene therapy
Donor Types and Outcomes of Transplantation in Myelofibrosis: A CIBMTR Study
Complete absence of GLUT1 does not impair human terminal erythroid differentiation

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals